Fentanyl inhalation - Alexza Pharmaceuticals

Drug Profile

Fentanyl inhalation - Alexza Pharmaceuticals

Alternative Names: AZ-003; EN 3294; Staccato fentanyl

Latest Information Update: 26 Mar 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alexza Pharmaceuticals
  • Class General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Pain

Most Recent Events

  • 08 Aug 2013 Biomarkers information updated
  • 26 Mar 2012 Development of fentanyl inhalation is still suspended
  • 26 Mar 2012 Fentanyl inhalation - Alexza Pharmaceuticals is available for licensing as of 26 Mar 2012. http://www.alexza.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top